Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Phase. Cord Blood Serum in the Treatment of Ocular Surface Diseases
Brief Summary: Human autologous serum (AS) eye drops have been successfully used in the treatment of severe ocular surface disorders and the enhancement of corneal wound healing, due to their growth factor (GF) content. Umbilical cord serum (UCS) contains even higher GF concentrations and the objective of the study was to prove whether UCS eye drops

1. are effective in the healing of corneal epithelial defects.
2. ameliorate the painful subjective symptoms


Options:
A: Inclusion Criteria:

* Age \> 18 years
* Severe Dry Eye, as defined by a OSDI score \> or = 40

Plus:

* Tear Break Up Time (TBUT) \< 5 seconds
* Cornea-conjunctival epithelial defects measured by Fluorescein staining and evaluation using the Oxford score.

Exclusion Criteria:

* No dry eye associated ocular disease
* Unable to comply protocol
* Severe anemia
* Previous use of autologous serum
* Concomitant use of other topical ocular drug
* Hypersensibility to any proposed interventions
B: Inclusion Criteria:

* Be between the ages of 18 and 79 years of age.
* Must understand and be able, willing and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

* Clinically significant eyelid deformity or eyelid movement disorder that is caused by conditions such as notch deformity, incomplete lid closure, entropion, ectropion, hordeola or chalazia..
* Previous ocular disease leaving sequelae or requiring current topical eye therapy other than for Dry Eye Disease, including, but not limited to: active corneal or conjunctival infection of the eye and ocular surface scarring.
* Active ocular allergy.
* LASIK or PRK surgery that was performed within one year of Visit 1.
* Started or changed the dose of chronic ocular medication within 30 days of visit 1.
* Contact lens worn within the past eight (8) hours.
* Any ophthalmologic drops within 2 hours of screening and visit 1 procedures.
* Pregnancy or lactation.
* Abnormality of nasolacrimal drainage (by history).
* Punctual plugs placement or cauterization within 30 days of Visit 1
* Started or changed the dose of chronic systemic medication known to affect tear production including, but not limited to antihistamines, antidepressants, diuretics, corticosteroids or immunomodulators within 30 days of Visit 1.
* Systemic disease known to affect tear production or loss including, but not limited to thyroid eye disease, that has been diagnosed or has not been stable within 30 days of Visit 1.
* Known hypersensitivity to any of the agents used in testing i.e. sodium fluorescein, lissamine green, oxybuprocaine or proparacaine.
C: Inclusion Criteria:

* to suffer from GVHD after bone marrow transplantation or SS-I
* presence of permanent or transient corneal epithelial defects scored \> 2 , according to DEWS severity classification
* to be in a general healthy condition
* signature of study consent for participation and personal data treatment.

Exclusion Criteria:

* to suffer from glaucoma and being under treatment with antiglaucomatous drugs
* to have received refractive surgery over the past year
D: Inclusion Criteria:

* Gender: male or female between 18\~70 years old without wearing contact lens.
* Diagnosis and classification: all patients should have the symptoms and signs of severe dry eye (conforming to grade 3 or 4 in DEWS2007). Should have at least two positive symptoms such as dryness, foreign body sensation, burning, asthenopia, red eye or secretion. Tear film breakup time (TFBUT) shorter than 5 seconds and/or Schirmer I less than 5 mm/5 min. Corneal fluorescein staining more than 6 scores and (or) more than 3 scores of bulbar conjunctiva lissamine green liquor.
* Both eyes of all patients were preliminarily examined, the patients with single eye that meets the criterion were also investigated. Objective indicators were investigated on each eye. While the ocular surface disease index (OSDI) scores and SF-36 results were evaluated on an individual base.
* All patients should not participate in other medical tests in the past 2 weeks.
* Should either not be treated with other medicine at present, or have been treated with other medicine but had paused more than 2 weeks

Exclusion Criteria:

* Pregnant or maternity: exclude the patients who are or will be pregnant or during breast feeding.
* Other surface diseases: exclude the patients who are suspected or complicated by other obvious ocular surface diseases.
* Severe systemic diseases: exclude the patients with severe primary diseases in heart, brain blood vessel, liver, kidney, hematopoietic system and so on.
* Intraocular surgery or trauma: exclude the patients with intraocular surgery or trauma during 6 months.
* Hormone replacement therapy : exclude post-menopausal women who are treated in hormone replacement therapy.
* Lacrimal punctum: exclude the patients who have been treated with lacrimal punctum in 1 month.
* Glaucoma or high IOP: exclude the patients who have glaucoma or high intraocular pressure (IOP) sores.
* Exclude the patients who are sensitive to steroid.
* Exclude the patients who can't wear the therapeutic bandage contact lens during the clinical study.
* Immunosuppressive therapies: exclude the patients who are using systemic steroid or immunosuppressive therapies which may influent the results of the evaluation of the therapeutic effect.
* Excluding the patients who may not be suitable for the clinical examination.

Answer: C